Literature DB >> 30293090

Long non-coding RNA AFAP1-AS1 plays an oncogenic role in promoting cell migration in non-small cell lung cancer.

Juan He1, Ke Wu1, Chenglin Guo1, Jian-Kang Zhou1, Wenchen Pu1, Yulan Deng1, Yuanli Zuo2, Yun Zhao2, Lunxu Liu1, Yu-Quan Wei1, Yong Peng3.   

Abstract

Long non-coding RNA (lncRNA) plays an important role in tumor progression and metastasis. Emerging evidence indicates that lncRNA actin filament-associated protein 1-antisense RNA 1 (AFAP1-AS1) is dysregulated in certain tumors. However, the function of AFAP1-AS1 in non-small cell lung cancer (NSCLC) remains elusive. In this study, we conducted global lncRNA profiling and identified that AFAP1-AS1 is significantly upregulated in NSCLC, suggesting that AFAP1-AS1 may be important for lung cancer development. For the first time, the transcription initiation and termination sites of AFAP1-AS1 were identified by rapid amplification of cDNA ends technology, and the sequencing data indicated that AFAP1-AS1 in lung cancer cells is a novel transcript variant. Through gain- and loss-of-function studies, AFAP1-AS1 was demonstrated to promote cell migration and invasion. Mechanistically, AFAP1-AS1 functions through positively regulating the expression of AFAP1 protein. On the other hand, the expression of lncRNA AFAP1-AS1 negatively correlates with CpG methylation status of its gene promoter, identified in both lung cancer cells and patient tissues, and treatment with DNA methyltransferase inhibitor decitabine significantly activates AFAP1-AS1 expression, strongly supporting that AFAP1-AS1 expression is tightly regulated by DNA methylation. Taken together, this study demonstrates that AFAP1-AS1 acts as an oncogene in NSCLC to promote cell migration partly by upregulating AFAP1 expression, while its own expression is controlled by DNA methylation, and highlights its diagnostic and therapeutic values for NSCLC patients.

Entities:  

Keywords:  AFAP1; AFAP1-AS1; Cell invasion; Cell migration; DNA methylation; Lung cancer

Mesh:

Substances:

Year:  2018        PMID: 30293090     DOI: 10.1007/s00018-018-2923-8

Source DB:  PubMed          Journal:  Cell Mol Life Sci        ISSN: 1420-682X            Impact factor:   9.261


  42 in total

1.  Long noncoding RNA AFAP1-AS1 facilitates tumor growth through enhancer of zeste homolog 2 in colorectal cancer.

Authors:  Jianming Tang; Guansheng Zhong; Jianhui Wu; Haiyan Chen; Yongshi Jia
Journal:  Am J Cancer Res       Date:  2018-05-01       Impact factor: 6.166

2.  Aberrant methylation of FBN2 in human non-small cell lung cancer.

Authors:  Hong Chen; Makoto Suzuki; Yohko Nakamura; Miki Ohira; Soichiro Ando; Tomohiko Iida; Takahiro Nakajima; Akira Nakagawara; Hideki Kimura
Journal:  Lung Cancer       Date:  2005-10       Impact factor: 5.705

3.  Overexpression of LncRNA AFAP1-AS1 predicts poor prognosis and promotes cells proliferation and invasion in gallbladder cancer.

Authors:  Fei Ma; Shou-Hua Wang; Qiang Cai; Ming-Di Zhang; Yong Yang; Jun Ding
Journal:  Biomed Pharmacother       Date:  2016-10-27       Impact factor: 6.529

4.  Src can regulate carboxy terminal interactions with AFAP-110, which influence self-association, cell localization and actin filament integrity.

Authors:  Y Qian; J M Baisden; E H Westin; A C Guappone; T C Koay; D C Flynn
Journal:  Oncogene       Date:  1998-04-30       Impact factor: 9.867

5.  Overexpression of lncRNA AFAP1-AS1 correlates with poor prognosis and promotes tumorigenesis in colorectal cancer.

Authors:  Feng Wang; Hongbing Ni; Feng Sun; Min Li; Lin Chen
Journal:  Biomed Pharmacother       Date:  2016-04-16       Impact factor: 6.529

6.  Reduced migration of MLH1 deficient colon cancer cells depends on SPTAN1.

Authors:  Inga Hinrichsen; Benjamin Philipp Ernst; Franziska Nuber; Sandra Passmann; Dieter Schäfer; Verena Steinke; Nicolaus Friedrichs; Guido Plotz; Stefan Zeuzem; Angela Brieger
Journal:  Mol Cancer       Date:  2014-01-24       Impact factor: 27.401

7.  Actin filament-associated protein 1 is required for cSrc activity and secretory activation in the lactating mammary gland.

Authors:  J M Cunnick; S Kim; J Hadsell; S Collins; C Cerra; P Reiser; D C Flynn; Y Cho
Journal:  Oncogene       Date:  2014-07-21       Impact factor: 9.867

8.  Genome-wide screen for differentially methylated long noncoding RNAs identifies Esrp2 and lncRNA Esrp2-as regulated by enhancer DNA methylation with prognostic relevance for human breast cancer.

Authors:  K Heilmann; R Toth; C Bossmann; K Klimo; C Plass; C Gerhauser
Journal:  Oncogene       Date:  2017-07-31       Impact factor: 9.867

9.  Long non-coding RNA AFAP1-AS1/miR-320a/RBPJ axis regulates laryngeal carcinoma cell stemness and chemoresistance.

Authors:  Zhennan Yuan; Cheng Xiu; Kaibin Song; Rong Pei; Susheng Miao; Xionghui Mao; Ji Sun; Shenshan Jia
Journal:  J Cell Mol Med       Date:  2018-07-04       Impact factor: 5.310

10.  edgeR: a Bioconductor package for differential expression analysis of digital gene expression data.

Authors:  Mark D Robinson; Davis J McCarthy; Gordon K Smyth
Journal:  Bioinformatics       Date:  2009-11-11       Impact factor: 6.937

View more
  15 in total

Review 1.  AFAP1-AS1: a rising star among oncogenic long non-coding RNAs.

Authors:  Fang Xiong; Kunjie Zhu; Su Deng; Hongbin Huang; Liting Yang; Zhaojian Gong; Lei Shi; Yi He; Yanyan Tang; Qianjin Liao; Jianjun Yu; Xiaoling Li; Yong Li; Guiyuan Li; Zhaoyang Zeng; Wei Xiong; Shanshan Zhang; Can Guo
Journal:  Sci China Life Sci       Date:  2021-05-13       Impact factor: 6.038

2.  Aberrant methylation-mediated downregulation of lncRNA CCND2 AS1 promotes cell proliferation in cervical cancer.

Authors:  Chengcheng Zhao; Jian Liu; Huazhang Wu; Jiaojiao Hu; Jianquan Chen; Jie Chen; Fengchang Qiao
Journal:  J Biol Res (Thessalon)       Date:  2020-06-26       Impact factor: 1.889

Review 3.  The Function of Non-Coding RNAs in Lung Cancer Tumorigenesis.

Authors:  Cornelia Braicu; Alina-Andreea Zimta; Antonia Harangus; Ioana Iurca; Alexandru Irimie; Ovidiu Coza; Ioana Berindan-Neagoe
Journal:  Cancers (Basel)       Date:  2019-04-30       Impact factor: 6.639

4.  Methylation and transcriptome analysis reveal lung adenocarcinoma-specific diagnostic biomarkers.

Authors:  Rui Li; Yi-E Yang; Yun-Hong Yin; Meng-Yu Zhang; Hao Li; Yi-Qing Qu
Journal:  J Transl Med       Date:  2019-09-27       Impact factor: 5.531

5.  Long noncoding RNA FAM3D-AS1 inhibits development of colorectal cancer through NF-κB signaling pathway.

Authors:  Ying Meng; Feng Yu
Journal:  Biosci Rep       Date:  2019-07-05       Impact factor: 3.840

6.  Long Noncoding RNA AFAP1-AS1 Promotes Cell Proliferation and Metastasis via the miR-155-5p/FGF7 Axis and Predicts Poor Prognosis in Gastric Cancer.

Authors:  Hong-Wu Ma; Da-Yong Xi; Jian-Zhong Ma; Min Guo; Li Ma; Dong-Hong Ma; Pei-Wu Li; Chang-An Guo
Journal:  Dis Markers       Date:  2020-01-19       Impact factor: 3.434

7.  Long Noncoding RNA GATA3-AS1 Promotes Cell Proliferation and Metastasis in Hepatocellular Carcinoma by Suppression of PTEN, CDKN1A, and TP53.

Authors:  Xuee Luo; Ning Zhou; Le Wang; Qinghua Zeng; Hongying Tang
Journal:  Can J Gastroenterol Hepatol       Date:  2019-12-02

8.  The long non-coding RNA SNHG4/microRNA-let-7e/KDM3A/p21 pathway is involved in the development of non-small cell lung cancer.

Authors:  Fan Wang; Qingqing Quan
Journal:  Mol Ther Oncolytics       Date:  2020-12-25       Impact factor: 7.200

9.  Long non-coding RNA AFAP1-AS1 accelerates the progression of melanoma by targeting miR-653-5p/RAI14 axis.

Authors:  Fei Liu; Lanting Hu; Yi Pei; Ke Zheng; Wei Wang; Shenglong Li; Enduo Qiu; Guanning Shang; Jiaming Zhang; Xiaojing Zhang
Journal:  BMC Cancer       Date:  2020-03-30       Impact factor: 4.430

10.  Exosome-transmitted lncRNA UFC1 promotes non-small-cell lung cancer progression by EZH2-mediated epigenetic silencing of PTEN expression.

Authors:  Xueyan Zang; Jianmei Gu; Jiayin Zhang; Hui Shi; Sinan Hou; Xueying Xu; Yanke Chen; Yu Zhang; Fei Mao; Hui Qian; Taofeng Zhu; Wenrong Xu; Xu Zhang
Journal:  Cell Death Dis       Date:  2020-04-02       Impact factor: 8.469

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.